Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Although metastatic disease is responsible for the majority of cancer deaths, tests of novel immunotherapies in mouse tumour models often focus on primary tumours without determining whether these therapies also target metastatic disease. This study examined the impact of depleting Foxp3+regulatory T cells (Treg), on lung metastases, using a mouse model of breast cancer. After Treg-depletion, generation of an immune response to the primary tumour was a critical determinant for limiting development of metastasis. Indeed, resection of the primary tumour abrogated any effect of Treg-depletion on metastases. In addition, whilst the immune response, generated by the primary tumour, prevented metastases development, it had little impact on controlling established disease. Collectively, the data indicate that metastatic cells in the lung are not controlled by immune responses induced by the primary tumour. These findings indicate that targeting Tregs alone will not suffice for treating lung metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a similar model, depletion of Treg cells potentiated the effect of ICIs when applied to primary tumours108.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [108]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Pre-metastatic niches: organ-specific homes for metastases
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 2×
“Recently, Costa and colleagues showed that a particular subset of CAF drives immunosuppression in triple-negative breast cancer [30].”
BackgroundOn the Origin of Cancer Metastasis
Seyfried, T. N., & Huysentruyt, L. C. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.v18.i1-2.40 · Cited by 1,196
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944 · cited 2×
“They are significantly enriched in many mouse and human tumours, and several studies have provided evidence that depletion of Treg promotes immune-mediated rejection at least of primary tumours ([9, 10] and reviewed in [8]).”
BackgroundSelective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease
Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G., Hamann, A., Wagner, H., Huehn, J., & Sparwasser, T. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061852 · Cited by 924
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912 · cited 1×
“Plates were left to dry, and the resulting blue colonies were counted, with each blue colony representing one metastatic cell [14].”
MethodKuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Liu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., Xu, X., Zheng, J., & Cao, X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.021 · Cited by 640
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Pulaski, B. A., & Ostrand‐Rosenberg, S. (1998) · PubMed · Cited by 394
Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9730 · Cited by 388
Danna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., & Ostrand-Rosenberg, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2646 · Cited by 371
Gil-Bernabé, A. M., Ferjančič, Š., Tlalka, M., Zhao, L., Allen, P. D., Im, J. H., Watson, K., Hill, S. A., Amirkhosravi, A., Francis, J. L., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376426 · Cited by 352
Mouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 331
Townsend, A., Bastin, J., Gould, K., Brownlee, G., Andrew, M., Coupar, B., Boyle, D., Chan, S., & Smith, G. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.4.1211 · Cited by 327
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
Bacac, M., & Stamenkovic, I. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151523 · Cited by 286
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 245
Self-citationHung, A. C. F. (1996) · Medical Entomology and Zoology · Cited by 206
Cancer metastasis as a therapeutic target
Sleeman, J., & Steeg, P. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.039 · Cited by 198
Bodogai, M., Lee Chang, C., Wejksza, K., Lai, J., Merino, M., Wersto, R. P., Gress, R. E., Chan, A. C., Hesdorffer, C., & Biragyn, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4184 · Cited by 136
Eisenblätter, M., Flores‐Borja, F., Lee, J. J., Wefers, C., Smith, H. L., Hueting, R., Cooper, M. S., Blower, P. J., Patel, D., Rodriguez‐Justo, M., et al. (2017) · Theranostics · doi:10.7150/thno.17138 · Cited by 130
Emerging roles of regulatory T cells in tumour progression and metastasis
Halvorsen, E. C., Mahmoud, S., & Bennewith, K. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9529-x · Cited by 80
Gebremeskel, S., Lobert, L. M., Tanner, K., Walker, B., Oliphant, T., Clarke, L. E., Dellaire, G., & Johnston, B. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0229 · Cited by 73
Scurr, M., Pembroke, T., Bloom, A., Roberts, D., Thomson, A., Smart, K., Bridgeman, H., Adams, R., Brewster, A., Jones, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2579 · Cited by 68
Self-citationMalamas, A. S., Hammond, S. A., Schlom, J., & Hodge, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.19967 · Cited by 22
Antigen Specificity Determines the Pro- or Antitumoral Nature of CD8+ T Cells
Cuff, S. M., Dolton, G. M., Matthews, R. J., & Gallimore, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804089 · Cited by 17
Self-citation
Cited by
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“In a similar model, depletion of T reg cells potentiated the effect of ICIs when applied to primary tumours 108 .”
Kos, K., Aslam, M. A., van de Ven, R., Wellenstein, M. D., Pieters, W., van Weverwijk, A., Duits, D. E. M., van Pul, K., Hau, C., Vrijland, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110447 · Cited by 60
The Multifaceted Role of Regulatory T Cells in Breast Cancer
Kos, K., & de Visser, K. E. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042920-104912 · Cited by 58
“S ee c op yr ig ht f or a pp ro ve d us e. depletion subsequently led to control of metastatic disease through the induction of protective immunity (Hughes et al. 2020).”
BackgroundTherapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer
Fattori, S., Roux, H., Connen, E., Robert, L., Gorvel, L., Roy, A. L., Houacine, J., Foussat, A., Chrétien, A.-S., & Olive, D. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0654 · Cited by 37
Metadata
- Authors
- Hughes, E., Lauder, S. N., Smart, K., Bloom, A., Scott, J., Jones, E., Somerville, M., Browne, M., Blainey, A., Godkin, A., Ager, A., & Gallimore, A.
- Affiliations
- University of Manchester (GB)
- Cardiff University (GB)
- Corresponding author
- Gallimore, Awen
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2020-05-23
- Volume
- 69
- Issue
- 10
- Pages
- 2063-2073
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC7511476
- OpenAlex
- W3026935474
- Cited by
- 15
- References
- 36
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 1
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Funders
- Tenovus (phd2013/L22)
- Wales Cancer Research Centre
- Cancer Research UK (C16731/A21200)
- Breast Cancer Now (2019DecPR1377)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- regulatory T cells, Foxp3, Treg depletion, breast cancer, lung metastasis, antitumor immunity, primary tumor, tumor resection, metastasis suppression, cancer immunotherapy
- MeSH terms
- Animals, Female, Immunotherapy, Lung Neoplasms, Lymphocyte Depletion, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.